MOPEAD Publications

July 17, 2019

AAIC 2019

This poster was presented at the AAIC 2019 in Los Angeles by Cambridge Cognition (or CANTAB). It outlines interim analysis of the Alzheimer's disease citizen science platform developed by the MOPEAD Project (or Run 1). This patient engagement model invited members of the general public in five European countries to take an online memory test with the possibility of receiving further health assessment or even a diagnosis in exchange for their data to be used as part of the study. 

May 13, 2019

Alzheimer's & Dementia, The Journal of the Alzheimer's Association

In most, if not all health systems, dementia is underdiagnosed, and when diagnosis occurs, it is typically at a relatively late stage in the disease process despite mounting evidence showing that a timely diagnosis would result in numerous benefits for patients, families, and society. Moving toward earlier diagnoses in Alzheimer's disease (AD) requires a conscientious and collective effort to implement a global strategy addressing the multiple causes hindering patient engagement at different levels of society. This article describes the design of the Models of Patient Engagement for Alzheimer's Disease project, an ongoing EU-funded public-private multinational initiative that will compare four innovative patient engagement strategies across five European countries regarding their ability to identify individuals with prodromal AD and mild AD dementia, which are “hidden” in their communities and traditionally not found in the typical memory clinic setting. The strategies include an online AD citizen science platform, an open house initiative at the memory clinics, and patient engagement at primary care and diabetologist clinics.

September 30, 2018

Dementia in Europe: The Alzheimer Europe Magazine

A special 16-page supplement showcasing the work of the MOPEAD was published alongside the Alzheimer Europe 2018 Dementia in Europe magazine. The supplement includes a general overview of the project, information about each of the project's work-streams and their goals, as well as interviews with the project leadership.

Please reload

©2018 MOPEAD

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreement No 115985. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations